Business, energy, technology, markets and global industry news from Business News Today

nAAVigator

PharmaDeviceNews nAAVigator
VectorBuilder and Lir Therapeutics are combining AAV capsid engineering, AI-guided design and translational development capabilities as they seek to narrow the gap between promising gene therapy vectors and clinically viable candidates. Representative image.
Pharma & Biotech

What the VectorBuilder and Lir Therapeutics alliance means for next-generation gene therapy vectors

VectorBuilder and Lir Therapeutics are linking AI-guided AAV capsid design with translational development to tackle gene therapy delivery barriers.

Read More